Results 31 to 40 of about 125,339 (239)

Chronic elevation of systemic glucagon-like peptide-1 following surgical weight loss: association with nausea and vomiting and effects on adipokines. [PDF]

, 2015
We determined whether persistent nausea and vomiting (N/V) symptoms following Roux-en-Y gastric bypass surgery is due to elevated systemic glucagon-like peptide-1 (GLP-1) and leptin in female non-diabetic subjects.
Al-Rasheid, N, Al-Sayrafi, M, Atherton, E, Gray, R, Marina-Gonzalez, N, Mohamed-Ali, V, Sufi, P   +6 more
core   +1 more source

Studies on Incretins and Cardiovascular Function [PDF]

, 2010
Background Type 2 diabetes (T2DM) is a strong risk factor for coronary heart disease (CHD). A great many diabetic subjects suffer from congestive heart failure (CHF), a condition with a high concomitant mortality.
Nathanson, David
core   +1 more source

Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review

Hepatic Medicine: Evidence and Research, 2020
Getnet Teshome,1 Sintayehu Ambachew,2 Alebachew Fasil,2 Molla Abebe2 1University of Gondar Comprehensive Specialized Hospital, University of Gondar, Gondar, Amhara, Ethiopia; 2Department of Clinical Chemistry, University of Gondar, Gondar, Amhara ...
Teshome G, Ambachew S, Fasil A, Abebe M
doaj  

Glucagon-Like Peptide-1 Protects Human Islets against Cytokine-Mediated β-Cell Dysfunction and Death: A Proteomic Study of the Pathways Involved [PDF]

, 2013
Glucagon-like peptide-1 (GLP-1) has been shown to protect pancreatic β-cells against cytokine-induced dysfunction and destruction. The mechanisms through which GLP-1 exerts its effects are complex and still poorly understood. The aim of this study was to
Ahlemann M., Alexandraki K., Baggio L. L., Bugliani M., Bulotta A., Cardozo A. K., Cardozo A. K., Chantal Mathieu, Chiu T. T., Cnop M., Cooper J. A., De Leon D. D., Dieter Rondas, Donath M. Y., Dotta F., Doyle M. E., Drucker D. J., Dunne J. L., D’Hertog W., Eizirik D. L., Etienne Waelkens, Fonseca S. G., Fred R. G., Gurzov E. N., Gysemans C. A., Harding H. P., Holst J. J., Hui H., Johannesen J., Kasper Lage, Kibbey R. G., Kutlu B., Kutlu B., Lage K., Larsen P. M., Lut Overbergh, Mann M., Marchetti P., Marchetti P., Marco Bugliani, Masini M., Mathilde Masini, Meloni A. R., Mueller C. M., Piero Marchetti, Planas R., Poukkula M., Rabinovitch A., Rasschaert J., Rieneck K., Rolin B., Rondas D., Sarkar S. A., Sarkar S. A., Sparre T., Srinivasan M., Suen C. S., Tews D., Thurmond D. C., Tourrel C., Velmurugan K., Wang C., Wannes D’Hertog, Watanabe T., Weber A.   +64 more
core   +2 more sources

Chronic exposure to GLP-1 increases GLP-1 synthesis and release in a pancreatic alpha cell line (α-TC1): evidence of a direct effect of GLP-1 on pancreatic alpha cells.

PLoS ONE, 2014
Aims/hypothesisIncretin therapies, which are used to treat diabetic patients, cause a chronic supra-physiological increase in GLP-1 circulating levels.
Salvatore Piro, Loriana G Mascali, Francesca Urbano, Agnese Filippello, Roberta Malaguarnera, Salvatore Calanna, Agata M Rabuazzo, Francesco Purrello   +7 more
doaj   +1 more source

Recent advances in understanding the role of glucagon-like peptide 1 [version 1; peer review: 2 approved]

F1000Research, 2020
The discovery that glucagon-like peptide 1 (GLP-1) mediates a significant proportion of the incretin effect during the postprandial period and the subsequent observation that GLP-1 bioactivity is retained in type 2 diabetes (T2D) led to new therapeutic ...
Josh Reed, Stephen Bain, Venkateswarlu Kanamarlapudi   +2 more
doaj   +1 more source

Reduction in GLP-1 secretory capacity may be a novel independent risk factor of coronary artery stenosis

Scientific Reports, 2021
Multiple factors regulate glucagon-like peptide-1 (GLP-1) secretion, but a group of apparently healthy subjects showed blunted responses of GLP-1 secretion in our previous study.
Chihiro Nagase, Masaya Tanno, Hidemichi Kouzu, Takayuki Miki, Junichi Nishida, Naoto Murakami, Nobuaki Kokubu, Nobutaka Nagano, Ryo Nishikawa, Nobuhiro Yoshioka, Tohru Hasegawa, Hiroyuki Kita, Akihito Tsuchida, Hirofumi Ohnishi, Tetsuji Miura   +14 more
doaj   +1 more source

Discrepancy between the Actions of Glucagon-like Peptide-1 Receptor Ligands in the Protection of the Heart against Ischemia Reperfusion Injury

Pharmaceuticals, 2022
Tirzepatide is a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist and a promising therapy for type 2 diabetes mellitus (T2DM). GLP-1 is an incretin hormone with therapeutic potential beyond type
Ali Ismaeil, Fawzi Babiker, Suleiman Al-Sabah   +2 more
doaj   +1 more source

Five‐Year Disease Progression in Synuclein Seeding Positive Sporadic Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To provide a comprehensive description of disease progression in synuclein seeding assay (SAA) positive sporadic Parkinson Disease participants, using Neuronal Synuclein Disease integrated biological and functional impairment staging framework.
Paulina Gonzalez‐Latapi, Caroline Gochanour, Seung Ho Choi, Hyunkeun Cho, Chelsea Caspell‐Garcia, Christopher Coffey, Michael Brumm, David‐Erick Lafontant, Yuge Xiao, Thomas Tropea, John Seibyl, Caroline Tanner, Charles S. Venuto, Karl Kieburtz, Lana M. Chahine, Kathleen L. Poston, Andrew Siderowf, Kenneth Marek, Tanya Simuni, The Parkinson's Progression Markers Initiative   +19 more
wiley   +1 more source

Glucagon-like peptide-1 (GLP-1) increases in plasma and colon tissue prior to estrus and circulating levels change with increasing age in reproductively competent Wistar rats

, 2017
There is a well-documented association between cyclic changes to food intake and the changing ovarian hormone levels of the reproductive cycle in female mammals.
Johnson, Michelle L., Saffrey, M. Jill, Taylor, Victoria J.   +2 more
core   +1 more source